Homepage > Company > Media > Pharma News > 2019 > Amgen's postmenopausal osteoporosis drug wins FDA panel backing

Amgen's postmenopausal osteoporosis drug wins FDA panel backing

(Reuters) - An advisory panel to the U.S. Food and Drug Administration on Wednesday recommended Amgen Inc’s osteoporosis treatment for postmenopausal women at high risk for fracture, saying the benefits of the drug outweighed its risks.

The panel voted 15-1 in favor of the monthly injection, developed with Belgium-based UCB SA, that works as a bone forming agent. The drug, Evenity, helps reduce the risk of fracture by increasing bone formation and inhibiting break down of bone minerals.

Three other members of the panel voted in favor of the drug but proposed approving it for a different indication.

The FDA is not mandated to follow the recommendation of the panel, but generally does.

JANUARY 16, 2019

https://www.reuters.com/

Read also

EC approves AstraZeneca’s Fasenra for EGPA treatment

The European Commission (EC) has approved AstraZeneca‘s Fasenra (benralizumab) as an add-on therapy for adults with relapsing or refractory eosinophilic granulomatosis with polyangii...

Genprex reports positive preclinical gene therapy data

Genprex, Inc., a clinical-stage gene therapy company, announced positive preclinical results for its lead drug candidate, Reqorsa® (quratusugene ozeplasmid) Gene Therapy, at the recent EORTC-...

Astellas withdraws Europe ACP application for AMD treatment

Astellas Pharma has announced the withdrawal of its marketing authorisation application for IZERVAY (avacincaptad pegol, ACP) intravitreal solution to treat geographic atrophy (GA) sec...

New report demands greater understanding of the impact of change on academia

Digital Science, a technology company serving stakeholders across the research ecosystem, is today calling for greater awareness of the impact that a myriad of fast-developing technologies are having ...